Journal: bioRxiv

Article Title: CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation

doi: 10.64898/2026.04.08.717301

Figure Lengend Snippet: (A) Representative images of adhesion assay using Calcein-AM stained CA19-9 negative (top) and positive (bottom) cells adhered to HUVECs. Scale bars = 100 μm. (B) Quantification of adhered CA19-9 neg and CA19-9 pos FC1199 (left), KPCY (middle) and FC1245 (right) cells per field. (C, D) Quantification of adhered CA19-9 pos FC1199 cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (C) and anti-human E-selectin antibody (BBA16; αSELE) (D) compared with isotype control (ISO). (E, F) Quantification of adhered hM19a 2D cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (E) and anti-human E-selectin antibody (BBA16; αSELE) (F) compared with isotype control (ISO). (G) Quantification of adhered Capan-2 cells after FUT3 knockout (sgFUT3) compared with a negative control (sgCtrl). *Data are presented as mean ± SD. Data are representative of at least two independent experiments. Statistical significance was determined by unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.

Article Snippet: Alternatively, HUVECs were incubated with mouse IgG (Leinco Technologies, Inc., I-536) or anti-human E-selectin Ab (R&D Systems, BBA16) at 25 μg/mL for 30 minutes at 37°C.

Techniques: Cell Adhesion Assay, Staining, Control, Knock-Out, Negative Control, Two Tailed Test

Journal: bioRxiv

Article Title: CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation

doi: 10.64898/2026.04.08.717301

Figure Lengend Snippet: (A) Schema of study design for metastatic seeding analysis in (B, C). (B) Representative YFP IHC of liver sections one day after splenic injection of CA19-9 neg or CA19-9 pos KPCY cells. Scale bar = 200 μm. (C) Quantification of YFP+ tumor cells in liver sections of WT mice injected with CA19-9 neg or CA19-9 pos KPCY cells, normalized by tissue area (mm²). (D) Schema of study design in (E-H). (E) Representative macroscopic images of livers isolated from WT (left) and E-selectin KO (right) mice injected with CA19-9 pos cells. Scale bar = 1 cm. (F, G) Quantification of liver weight (F) and of liver weight normalized by body weight (G). (H) Quantification of CK19 positive area (%) across the whole liver sections. (I) Schema of study design in (J) (J) Quantification of YFP+ tumor cells in liver sections of WT and E-selectin KO mice injected with CA19-9 pos KPCY cells, normalized by tissue area (mm²). (K) Schema of study design in (L, M) (L, M) Quantification of CA19-9 pos KPCY cells in liver sections of WT mice injected with CA19-9 pos KPCY cells and treated with isotype control or anti-CA19-9 antibody (5B1; αCA19-9) (L), or isotype control or anti-mouse E-selectin antibody (9A9; αSele) (M), normalized by tissue area (mm²). *Data are presented as mean ± SD. Each dot represents an individual mouse. For A-H, mice were injected with 1 × 10 5 tumor cells per mouse. For I-M, mice were injected with 3 × 10 5 tumor cells per mouse. Statistical significance was calculated using unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.

Article Snippet: Alternatively, HUVECs were incubated with mouse IgG (Leinco Technologies, Inc., I-536) or anti-human E-selectin Ab (R&D Systems, BBA16) at 25 μg/mL for 30 minutes at 37°C.

Techniques: Injection, Isolation, Control, Two Tailed Test

Journal: Frontiers in Immunology

Article Title: Molecular determinants of STEC-HUS: from complement activation to microvascular thrombosis

doi: 10.3389/fimmu.2026.1749811

Figure Lengend Snippet: Prothrombotic effects of STEC-HUS serum are dependent on WPB exocytosis from endothelial cells. P-selectin (A) and vWF (B) expression on unstimulated HMEC-1 exposed to serum from patients with acute STEC-HUS (n = 5 for P-selectin experiments; n = 6 for vWF experiments), in the presence or in the absence of different complement inhibitors (sCR1, 150 µg/mL; factor B inhibitor, iptacopan,10 µM; eculizumab 100 µg/mL) or to a pool of control sera (normal human serum, NHS), run in parallel. Results are shown as pixel 2 /high-power field (HPF) of stained surface area. Data are mean ± SD. Circles represent single patients’ data. The addition of either sCR1, or iptacopan or eculizumab to patient’s serum significantly decrease both P-selectin and vWF expression induced by patient’s serum alone. *P < 0.05 vs STEC-HUS serum alone (ANOVA, followed by Tukey’s multiple comparisons test for data of P-selectin expression and by Holm-Šídák’s multiple comparisons test for data of vWF expression). (C) Endothelial surface area covered by thrombi on ADP-activated HMEC-1 exposed to serum from STEC-HUS patients collected during the acute phase of the disease and then perfused with whole blood. Before the experiments, HMEC-1 were left for 16 hours with medium added or not with the RalA inhibitor BQU57 (10 µM). Data are expressed as mean ± SD of percentages of serum-induced thrombus formation in respect to a pool of control sera (normal human serum, NHS), run in parallel in each experiment and set as 100% (n = 3 independent experiments). Circles indicate single patients’ data. Horizontal dashed lines indicate upper and lower limits of the normal range . *P < 0.05 (paired Student’s t test). (D) Representative confocal microscopy images (original magnification X200) of experiments of thrombus formation (green staining) relative to Figure 6C . Scale bar: 100 µm.

Article Snippet: Cells were washed again and treated with the following specific antibodies: FITC-conjugated rabbit anti-human C3c-complement (Dako, that recognizes C3c, part of C3 and C3b, 1:300 final dilution in Dapi 1 μg/mL); or rabbit anti-human complement C5b-9 complex (Calbiochem, 1:200 final dilution in PBS1X) followed by FITC-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, 1:50 final dilution in 1 μg/mL Dapi); or goat anti-human C4 (Abcam, 1:100 final dilution in PBS1X) followed by Cy3-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, 1:200 final dilution in Dapi 1 μg/mL); or FITC-conjugated anti-human IgG (Sigma Aldrich, 1:32 final dilution in 1 μg/mL Dapi); or mouse anti-human P-selectin (R&D System, 20 μg/mL final concentration in PBS1X), followed by Cy3-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, 1:60 final dilution in 1 μg/mL Dapi); or rabbit anti-human vWF (Dako, 10 μg/mL final concentration in PBS1X), followed by Cy3-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, 1:50 final dilution in 1 μg/mL Dapi).

Techniques: Expressing, Control, Staining, Confocal Microscopy

Journal: Pathogens

Article Title: Early Platelet Dysfunction in Sepsis: An ICU Pilot Study

doi: 10.3390/pathogens15020196

Figure Lengend Snippet: ( A – C ): P-selectin expression on unstimulated ( A ), ADP-stimulated ( B ), and TRAP-stimulated ( C ) platelets of patients with sepsis and septic shock compared to healthy controls at T0, T1, and T2. Results are expressed as a % of P-selectin-positive platelets, identified as CD42 B-positive events. ( A ) T0 vs. CTRL: p bonf = 0.0006; T1 vs. CTRL: p bonf = 0.0006; T2 vs. CTRL: p bonf = 0.12; ( B ) T0 vs. CTRL: p bonf = 0.026; T1 vs. CTRL: p bonf = 0.056; T2 vs. CTRL: p bonf = 0.037; ( C ) n.s.= not significant. Bonferroni correction was applied for all pairwise comparisons; p -values (p bonf ) are reported. Sample size: n = 10 at T0 and T2, n = 9 at T1. * p < 0.05, ** p < 0.005. ns = no significance.

Article Snippet: Measurement of soluble P-selectin and soluble CD40 ligand in serum was per-formed using the anti-human P-selectin (R&D System, Inc., Minneapolis, MN, USA) and human CD40L/TNFSF5 (R&D System, Inc., Minneapolis, MN, USA) immunoassay kits ac-cording to the manufacturer’s instructions.

Techniques: Expressing

Journal: Pathogens

Article Title: Early Platelet Dysfunction in Sepsis: An ICU Pilot Study

doi: 10.3390/pathogens15020196

Figure Lengend Snippet: ( A , B ): Patient soluble CD40L ( A ) and soluble P-selectin ( B ) plasma levels at times T0, T1, and T2 compared to controls. ( A ) T0 vs. CTRL: p bonf = 0.05; T1 vs. CTRL: p bonf = 0.04; T2 vs. CTRL: p bonf = 0.018. Bonferroni correction was applied for all pairwise comparisons; p -values (p bonf ) are re-ported. Sample size: n = 10 at T0 and T2, n = 9 at T1. * p < 0.05. ns = no significance.

Article Snippet: Measurement of soluble P-selectin and soluble CD40 ligand in serum was per-formed using the anti-human P-selectin (R&D System, Inc., Minneapolis, MN, USA) and human CD40L/TNFSF5 (R&D System, Inc., Minneapolis, MN, USA) immunoassay kits ac-cording to the manufacturer’s instructions.

Techniques: Clinical Proteomics